Department of Medicine, Division of Hematology & Oncology, University of Virginia Cancer Center, PO Box 800334, Charlottesville, VA, 22908-0334, USA.
Department of Biochemistry and Molecular Genetics, Charlottesville, VA, 22908, USA.
Curr Hematol Malig Rep. 2020 Apr;15(2):103-112. doi: 10.1007/s11899-020-00565-6.
The past decade in LGL leukemia research has seen increased pairing of clinical data with molecular markers, shedding new insights on LGL leukemia pathogenesis and heterogeneity. This review summarizes the current standard of care of LGL leukemia, updates from clinical trials, and our congruent improved understanding of LGL pathogenesis.
Various clinical reports have identified associations between stem, bone marrow, and solid organ transplants and incidence of LGL leukemia. There is also a potential for underdiagnosis of LGL leukemia within the rheumatoid arthritis patient population, emphasizing our need for continued study. Preliminary results from the BNZ-1 clinical trial, which targets IL-15 along with IL-2 and IL-9 signaling pathways, show some evidence of clinical response. With advances in our understanding of LGL pathogenesis from both the bench and the clinic, exciting avenues for investigations lie ahead for LGL leukemia.
过去十年,LGL 白血病的研究已经将临床数据与分子标志物进行了更多的配对,从而对 LGL 白血病的发病机制和异质性有了新的认识。本综述总结了 LGL 白血病的当前治疗标准、临床试验的最新进展以及我们对 LGL 发病机制的一致深入理解。
各种临床报告已经确定了干细胞、骨髓和实体器官移植与 LGL 白血病发病之间的关联。类风湿关节炎患者人群中也存在 LGL 白血病诊断不足的潜在情况,这强调了我们需要持续研究。靶向 IL-15 以及 IL-2 和 IL-9 信号通路的 BNZ-1 临床试验的初步结果显示出一些临床反应的证据。随着我们对 LGL 发病机制的理解在临床和基础研究两方面都取得了进展,LGL 白血病的研究有了令人兴奋的新方向。